Bone graft substitutes span the range of processed allograft bone to synthetic materials and synthetic-biologic composites. During the past year, studies showed that there is considerable variability in the bone-inductive quality of demineralized freeze-dried bone allografts; the providers of these materials are working to find ways of ensuring quality by identifying donor characteristics that are responsible. New bone void fillers also became available. Calcium sulfate pellets were approved by the Food and Drug Administration for use in orthopedics in the United States. Among the new bone graft substitutes presented at the 1997 Orthopaedic Research Society meeting at the American Academy of Orthopedic Surgeons 1997 meeting (San Francisco, CA) were polylactic acid-polyglycolic acid scaffolds and a hyaluronic acid-basic fibroblast growth factor composite. Bone morphogenetic proteins continue to be studied both in animals and in humans. It is becoming clear that these factors may be most valuable for treatment of chronic nonunions and spine fusion. Scientists are also beginning to examine cell and gene therapies for promoting bone formation.
ASJC Scopus subject areas